CH676600A5 - - Google Patents

Download PDF

Info

Publication number
CH676600A5
CH676600A5 CH2240/87A CH224087A CH676600A5 CH 676600 A5 CH676600 A5 CH 676600A5 CH 2240/87 A CH2240/87 A CH 2240/87A CH 224087 A CH224087 A CH 224087A CH 676600 A5 CH676600 A5 CH 676600A5
Authority
CH
Switzerland
Prior art keywords
cells
cell
bcgf
ligand
proliferation
Prior art date
Application number
CH2240/87A
Other languages
German (de)
English (en)
Inventor
Jeffrey A Ledbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of CH676600A5 publication Critical patent/CH676600A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CH2240/87A 1986-06-13 1987-06-15 CH676600A5 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (1)

Publication Number Publication Date
CH676600A5 true CH676600A5 (nl) 1991-02-15

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2240/87A CH676600A5 (nl) 1986-06-13 1987-06-15

Country Status (22)

Country Link
JP (1) JPH0762040B2 (nl)
KR (1) KR910004100B1 (nl)
AT (1) AT398437B (nl)
AU (1) AU617087B2 (nl)
BE (1) BE1000587A4 (nl)
CA (1) CA1338781C (nl)
CH (1) CH676600A5 (nl)
CY (1) CY1681A (nl)
DE (1) DE3719398C2 (nl)
DK (1) DK173940B1 (nl)
FR (1) FR2607136B1 (nl)
GB (1) GB2191494B (nl)
GR (1) GR870930B (nl)
HK (1) HK10293A (nl)
IE (1) IE60486B1 (nl)
IL (1) IL82841A (nl)
IT (1) IT1208649B (nl)
LU (1) LU86919A1 (nl)
NL (1) NL195022C (nl)
PT (1) PT85073B (nl)
SE (1) SE504675C2 (nl)
SG (1) SG118992G (nl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IE871563L (en) 1987-12-13
BE1000587A4 (fr) 1989-02-14
PT85073A (en) 1987-07-01
FR2607136B1 (fr) 1989-09-15
IL82841A0 (en) 1987-12-20
GB8713650D0 (en) 1987-07-15
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
JPH0762040B2 (ja) 1995-07-05
CA1338781C (en) 1996-12-10
DE3719398C2 (de) 1996-03-28
AU617087B2 (en) 1991-11-21
SE8702463L (sv) 1987-12-14
JPS6480299A (en) 1989-03-27
AU7421487A (en) 1987-12-17
SE504675C2 (sv) 1997-04-07
IT8720899A0 (it) 1987-06-12
NL8701371A (nl) 1988-01-04
LU86919A1 (fr) 1989-03-08
DE3719398A1 (de) 1988-01-28
KR910004100B1 (ko) 1991-06-22
SG118992G (en) 1993-01-29
IE60486B1 (en) 1994-07-27
GB2191494A (en) 1987-12-16
IL82841A (en) 1992-11-15
AT398437B (de) 1994-12-27
GB2191494B (en) 1990-08-22
IT1208649B (it) 1989-07-10
KR880000582A (ko) 1988-03-28
GR870930B (en) 1987-12-16
PT85073B (pt) 1990-07-31
SE8702463D0 (sv) 1987-06-12
HK10293A (en) 1993-02-19
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
FR2607136A1 (fr) 1988-05-27
DK302287A (da) 1987-12-14

Similar Documents

Publication Publication Date Title
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69119278T2 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
DE60019111T2 (de) Verfahren zur zellseparation unter verwendung von immunorosetten
US5247069A (en) Ligands and methods for augmenting B-cell proliferation
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
Hale et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement
Ledbetter et al. Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
DE3688637T2 (de) Löslicher Interleukin-2-Rezeptor als Anzeiger eines bösartigen Tumors und Verfahren zu dessen Nachweis.
Trowbridge et al. Murine cell surface transferrin receptor: studies with an anti‐receptor monoclonal antibody
DE3751214T2 (de) Monoklonale Antikörper gegen Immunglobulin G Fc-Rezeptoren auf humane mononukleare Phagozyten; bifunktionelle Antikörper; ziel-spezifische Effektorzellen; gezielte Makrophagen und Immunoassays.
DE69303494T2 (de) Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
DE69033631T2 (de) Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
DE69131331T2 (de) Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
DE4244715C2 (de) Verfahren zur Herstellung individuum-spezifischer, gegen Tumorantigene gerichtete monoklonale Antikörper
DE19600589C1 (de) Antikörper A3C6E2
DE69431526T2 (de) Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
DE19727814C1 (de) Anitkörper 4G8B4B12
DE68914016T2 (de) Identifizierung von NK-Zellen und cytotoxische T-Lymphozyten.
CH676600A5 (nl)
AT400956B (de) Verfahren zur gewinnung eines liganden und verfahren zur unterdrückung der proliferation von bp50 exprimierenden zellen
DE68912353T2 (de) Leu-23: Monoclonaler Antikörper zur Überwachung von Leukozyten-Aktivierung.
EP0863157B1 (de) Anti-Megakaryozyten monoklonaler Antikörper 97A6
EP1276770A1 (de) Proteine mit hoher immunreaktivität sowie ein verfahren zu ihrer herstellung
DE180486T1 (de) Hybridzellen die antiidiotypischen antikoerpern sekretieren, monoklonale antikoerper durch diese hybridzellen sekretiert, ihre herstellung und ihre verwendung.

Legal Events

Date Code Title Description
PL Patent ceased